News
Metastatic prostate cancer: cabazitaxel shows quality of life benefits over both abiraterone and enzalutamide
In addition to previously reported survival benefits, the taxane cabazitaxel improved quality of life in patients with advanced metastatic prostate cancer compared to the androgen signalling targeted inhibitors abiraterone and enzalutamide, reports the latest analysis of the CARD trial (Fizazi…
Combined therapies offer the key to drug-resistant cancer
For the first time, an investigator initiated phase 1b study tested the combination of the PARP inhibitor olaparib, and the AKT inhibitor capivasertib, and showed this combination was well tolerated and achieved durable responses in patients with treatment-refractory breast, ovarian…
New European Code of Cancer Practice defines patient rights along the cancer pathway
The European Code of Cancer Practice was launched on 23rd September in Brussels by the European Cancer Organisation to empower citizens with 10 key ‘overarching’ rights and reduce cancer care inequalities across Europe. “This powerful new tool sets out the…
Preclinical model identifies predictors of checkpoint inhibitor response
A study published in PNAS (Chen IX, et al. PNAS 2020) of a new mouse model has enabled the identification of distinct gene signatures that distinguish responders from non-responders to immune checkpoint blockade (ICB). “Our findings provide a general approach…
New transatlantic partnership to regain the momentum of cancer research
Building on the existing Cancer Research UK (CRUK) Grand Challenges initiative, a broader international collaboration has now been forged in partnership with the National Cancer Institute (NCI) in the US. This new Cancer Grand Challenges has been launched to seek…
ESMO provides first recommendations on use of next-generation sequencing in metastatic cancer
Patients with metastatic non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian cancers and cholangiocarcinoma should be offered next-generation sequencing (NGS) for profiling tumour samples, concludes an expert panel from the European Society for Medical Oncology (ESMO) in their review (Mosele…
COVID-19 diagnostic delays predicted to increase cancer deaths
Substantial increases in the number of avoidable cancer deaths in England are predicted as a result of diagnostic delays due to the COVID-19 pandemic, report two modeling studies published in the August issue of Lancet Oncology. Both studies underline the…
20-year WHI follow-up study finds oestrogen selectively protects against breast cancer in women who have undergone hysterectomy
A 20-year follow-up of the two Women’s Health Initiative (WHI) hormone replacement studies found that, among postmenopausal women with prior hysterectomy, use of oestrogen in comparison to placebo was associated with lower breast cancer incidence and mortality, while among those…
Dietary counseling remains cornerstone of cachexia management, say new ASCO guidelines
For cancer cachexia, dietary counseling should be offered with the goal of providing patients and caregivers with management advice, conclude the first guidelines on cachexia ever published by the American Society of Clinical Oncology (ASCO). In the absence of evidence,…
Dietary guidelines need reform to meet global health and environmental goals
National dietary guidelines in most countries need to be reformed to take into account health and environmental targets, concludes a study published in the BMJ (published online July 15). The international study, by UK, US and Australian investigators, found around…